Skip to content

Study · In vitro (cells) · mouse · 2011

3 results

Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease.

Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH

Human molecular genetics25 Aug 2011Cited by 549 (Europe PMC)

PMID21873260 (opens in a new tab)PMCIDPMC3209824 (opens in a new tab)DOI10.1093/hmg/ddr381 (opens in a new tab)PepBankPUB-21873260
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In primary neurons from Tg2576 mice, the mitochondria-targeted antioxidant SS31 restored mitochondrial transport.

    In plain wordsIn mouse nerve cells from an Alzheimer's disease model, SS31 restored the movement of mitochondria.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial transport
    Study

    mousen: not reported in source

    Primary neurons from Tg2576 AbetaPP mice with oligomeric Abeta
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    we found that the mitochondria-targeted antioxidant SS31 restored mitochondrial transport
    1 context sentence
    Summary · context
    Using primary neurons from a well-characterized Aβ precursor protein transgenic (AβPP) mouse model (Tg2576 mouse line), for the first time, we studied mitochondrial activity, including axonal transport of mitochondria, mitochondrial dynamics, morphology and function.
  2. 02LabIn vitro (cells)Mechanism

    In primary neurons from Tg2576 mice, SS31 restored synaptic viability.

    In plain wordsIn mouse nerve cells from an Alzheimer's disease model, SS31 restored the health of synapses.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSynaptic viability
    Study

    mousen: not reported in source

    Primary neurons from Tg2576 AbetaPP mice with oligomeric Abeta
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    we found that the mitochondria-targeted antioxidant SS31 restored mitochondrial transport and synaptic viability
    1 context sentence
    Summary · context
    Using primary neurons from a well-characterized Aβ precursor protein transgenic (AβPP) mouse model (Tg2576 mouse line), for the first time, we studied mitochondrial activity, including axonal transport of mitochondria, mitochondrial dynamics, morphology and function.
  3. 03LabIn vitro (cells)Mechanism

    In primary neurons from Tg2576 mice, SS31 decreased the percentage of defective mitochondria.

    In plain wordsIn mouse nerve cells from an Alzheimer's disease model, SS31 lowered the share of damaged mitochondria.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePercentage of defective mitochondria
    Study

    mousen: not reported in source

    Primary neurons from Tg2576 AbetaPP mice with oligomeric Abeta
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    we found that the mitochondria-targeted antioxidant SS31 restored mitochondrial transport and synaptic viability, and decreased the percentage of defective mitochondria
    1 context sentence
    Summary · context
    Using primary neurons from a well-characterized Aβ precursor protein transgenic (AβPP) mouse model (Tg2576 mouse line), for the first time, we studied mitochondrial activity, including axonal transport of mitochondria, mitochondrial dynamics, morphology and function.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.